Table 2.
Post-treatment characteristics
| mFOLFIRINOX (n = 30) | Other adjuvants (n = 28) | All (n = 58) | P | |
|---|---|---|---|---|
| Preoperative therapy | ||||
| Chemotherapy | ||||
| Cyclesa | 8 (5–15) | 9 (2–16) | 8 (2–16) | 0.591 |
| Duration, monthsa | 4.1 (1.9–8.1) | 4.7 (0.4–11.7) | 4.3 (0.4–11.7) | 0.234 |
| Radiation | ||||
| Conventional | 0 | 1 (3.6) | 1 (1.7) | |
| IMRT | 0 | 1 (3.6) | 1 (1.7) | |
| SBRT | 3 (10.0) | 3 (10.7) | 6 (10.3) | |
| Re-staged resectability | 0.337 | |||
| RPC | 8 (26.7) | 5 (17.9) | 13 (22.4) | |
| BRPC | 21 (70.0) | 21 (75.0) | 42 (72.4) | |
| LAPC | 1 (3.3) | 2 (7.1) | 3 (5.2) | |
| Surgery | 0.021 | |||
| Pancreaticoduodenectomy | 24 (80.0) | 15 (53.6) | 39 (67.3) | |
| Distal pancreatectomy | 6 (20.0) | 11 (39.3) | 17 (29.3) | |
| Subtotal or total pancreatectomy | 0 (0.0) | 2 (7.1) | 2 (3.4) | |
| Postoperative ECOG performance score | 0.354 | |||
| 0–1 | 26 (86.7) | 27 (96.4) | 53 (91.4) | |
| ≥ 2 | 4 (13.3) | 1 (3.6) | 5 (8.6) | |
| Cellular differentiation | 0.607 | |||
| WD to MD | 23 (76.7) | 23 (82.1) | 46 (79.3) | |
| PD | 7 (23.3) | 5 (17.9) | 12 (20.7) | |
| Resection margin | 0.648 | |||
| Negative (R0) | 24 (80.0) | 21 (75.0) | 45 (77.6) | |
| Positive (R1 or R2) | 6 (20.0) | 7 (25.0) | 13 (22.4) | |
| Tumor sizea (ypT) | 2.0 (0.1–5.0) | 3.0 (1.0–7.7) | 2.5 (0.1–7.7) | 0.001 |
| ≥ 2 cm | 18 (60.0) | 26 (92.9) | 44 (75.9) | 0.003 |
| LN metastasis (ypN) | 0.096 | |||
| Negative (N0) | 15 (50.0) | 8 (28.6) | 23 (39.7) | |
| Positive (N1 or N2) | 15 (50.0) | 20 (71.4) | 35 (60.3) | |
| TNM stageb | 0.064 | |||
| I | 15 (50.0) | 8 (28.6) | 23 (39.7) | |
| II | 13 (43.3) | 15 (53.6) | 28 (48.3) | |
| III | 2 (6.7) | 5 (17.8) | 7 (12.0) | |
| CAP score | 0.051 | |||
| 1 | 3 (10.0) | 1 (3.5) | 4 (6.9) | |
| 2 | 21 (70.0) | 15 (53.6) | 36 (62.1) | |
| 3 | 6 (20.0) | 12 (42.9) | 18 (31.0) | |
| Adjuvant therapy | ||||
| Duration, monthsa | 2.3 (0.1–7.7) | 3.4 (0.3–5.4) | 3.2 (0.1–7.7) | 0.840 |
| Dose reduction | 25 (83.3) | 10 (35.7) | 35 (60.3) | 0.001 |
| Percentage of reductiona | 20 (0–50) | 0 (0–45) | 15 (0–50) | 0.002 |
| Post-treatment CA 19-9a | 12 (5–3100) | 16 (5–11,100) | 14 (5–11,100) | 0.174 |
| ≥ 37 U/mL | 8 (26.7) | 9 (32.1) | 17 (29.3) | 0.647 |
| Recurrence | 0.005 | |||
| No | 16 (53.3) | 5 (17.9) | 21 (36.2) | |
| Yes | 14 (46.7) | 23 (82.1) | 37 (63.8) | |
Values in parentheses are percentages unless indicated otherwise
aValues are median (range)
bDefined according to the AJCC Cancer Staging Manual, 8th edition
IMRT intensity modulated radiation therapy, SBRT stereotactic body radiation therapy, RPC resectable pancreatic cancer, BRPC borderline resectable pancreatic cancer, LAPC locally advanced pancreatic cancer, ECOG Eastern cooperative oncology group, WD well differentiated, MD moderately differentiated, PD, poorly differentiated, CAP score College of American pathologists score, CA 19–9 carbohydrate antigen 19–9